UY37478A - Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash) - Google Patents

Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)

Info

Publication number
UY37478A
UY37478A UY0001037478A UY37478A UY37478A UY 37478 A UY37478 A UY 37478A UY 0001037478 A UY0001037478 A UY 0001037478A UY 37478 A UY37478 A UY 37478A UY 37478 A UY37478 A UY 37478A
Authority
UY
Uruguay
Prior art keywords
nafld
nash
treatment
pirfenidone
esteatohepatitis
Prior art date
Application number
UY0001037478A
Other languages
English (en)
Spanish (es)
Inventor
HERNÁNDEZ ALDANA Nadiel
Agustín Rogelio Magaña Castro José
Socorro Armendáriz Borunda Juan
Original Assignee
Cell Therapy And Tech S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapy And Tech S A De C V filed Critical Cell Therapy And Tech S A De C V
Publication of UY37478A publication Critical patent/UY37478A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
UY0001037478A 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash) UY37478A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).

Publications (1)

Publication Number Publication Date
UY37478A true UY37478A (es) 2018-05-31

Family

ID=61193005

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037478A UY37478A (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)

Country Status (21)

Country Link
US (3) US20190262325A1 (enExample)
EP (1) EP3539537A1 (enExample)
JP (2) JP2019535822A (enExample)
KR (2) KR20190084056A (enExample)
CN (2) CN110248646A (enExample)
AR (1) AR110057A1 (enExample)
AU (3) AU2017358367B2 (enExample)
CA (1) CA3043300A1 (enExample)
CL (1) CL2019001280A1 (enExample)
CO (1) CO2019004799A2 (enExample)
EC (1) ECSP19031851A (enExample)
IL (1) IL266519A (enExample)
JO (1) JOP20190102A1 (enExample)
MA (1) MA45754A1 (enExample)
MX (1) MX364040B (enExample)
PE (1) PE20191149A1 (enExample)
PH (1) PH12019501047A1 (enExample)
RU (1) RU2019116422A (enExample)
UY (1) UY37478A (enExample)
WO (1) WO2018088886A1 (enExample)
ZA (1) ZA201903012B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
CN111386115A (zh) * 2017-11-28 2020-07-07 艾格尔峰生物制药有限公司 用于治疗非酒精性脂肪性肝炎的方法和药物组合物
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
AU2021365528A1 (en) * 2020-10-23 2023-06-15 Hq Han Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
CN116159056A (zh) * 2023-03-09 2023-05-26 中南大学湘雅医院 一种氟非尼酮在制备非酒精性脂肪性肝炎药物中的应用
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
WO2010048716A1 (en) * 2008-10-29 2010-05-06 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Also Published As

Publication number Publication date
EP3539537A1 (en) 2019-09-18
AU2017358367A1 (en) 2019-05-30
PH12019501047A1 (en) 2019-12-11
JOP20190102A1 (ar) 2019-05-06
ZA201903012B (en) 2020-09-30
CA3043300A1 (en) 2018-05-17
AU2024200737A1 (en) 2024-02-22
MX2016014775A (es) 2018-05-10
RU2019116422A3 (enExample) 2021-04-09
JP2019535822A (ja) 2019-12-12
CO2019004799A2 (es) 2019-07-31
MA45754A1 (fr) 2019-12-31
AR110057A1 (es) 2019-02-20
PE20191149A1 (es) 2019-09-02
US20250325530A1 (en) 2025-10-23
AU2017358367B2 (en) 2023-11-09
CN110248646A (zh) 2019-09-17
RU2019116422A (ru) 2020-12-11
KR20190084056A (ko) 2019-07-15
ECSP19031851A (es) 2019-06-30
KR20240065330A (ko) 2024-05-14
MX364040B (es) 2019-04-11
CN115969802A (zh) 2023-04-18
US20230181550A1 (en) 2023-06-15
JP2022173344A (ja) 2022-11-18
IL266519A (en) 2019-07-31
CL2019001280A1 (es) 2019-07-19
WO2018088886A1 (es) 2018-05-17
AU2026200298A1 (en) 2026-02-05
US20190262325A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
AR110057A1 (es) Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld / nash)
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
GB201517215D0 (en) Use of cannabinoids in the treatment of inflammatory skin diseases
SI3378859T1 (sl) Derivat benzofurana, postopek za njegovo pripravo in njegova uporaba v medicini
CL2014003444A1 (es) Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes.
SI3310389T1 (sl) Topični sestavki, ki obsegajo kortikosteroid in retinoid za zdravljenje psoriaze
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
HRP20190573T1 (hr) Piranokromenil fenol derivat, i farmaceutska kompozicija za liječenje metaboličkog sindroma ili inflamatorne bolesti
HUE042242T2 (hu) Szteroid vegyület májeredetû enkefalopátia kezelésében történõ alkalmazásra
MX2018005628A (es) Tratamientos de grasa acumulada con acido desoxicolico y sales del mismo.
MX2016011025A (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2016010722A (es) Composiciones que contienen extractos de curcuma longa y echinacea angustifolia que son utiles para reducir la inflamacion periferica y el dolor.
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
EP3344233A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF DOXYCLYCLIN AND THEIR USE IN THE TREATMENT OF DOXYCLYCLIN-RELATED ILLNESSES AND SUFFERING
EP3270883C0 (en) Scalable vitamin composition unit dosage for the treatment of fat-soluble vitamin deficiencies
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
ZA201608558B (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
ITUB20160024A1 (it) Nuove composizioni topiche comprendenti acido usnico e loro uso in terapia.
FR3030270B1 (fr) Procede de traitement cosmetique et kit associe
GB201410869D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
IL255247A0 (en) Pharmaceutical formulation for the treatment of inflammatory changes to the rectum
CL2017000915A1 (es) Uso de ácido neridrónico o de su sal para el tratamiento de la osteoatrosis
ZA201903833B (en) Novel multitarget drug for treating diseases in mammals
HK1233946A1 (en) Topical composition for use in the treatment of inflammatory bowel disease
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20240409